Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients

HPB

Volumn 12, Issue 10, 2010, Pages 657-663

  Fayek, Sameh Adel ^a   Mantipisitkul, Wana ^b   Rasetto, Flavia ^b   Munivenkatappa, Raghava ^a   Barth, Rolf N ^a   Philosophe, Benjamin ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

cytomegalovirus; ganciclovir; solid organ transplant; valganciclovir

Indexed keywords

ACICLOVIR; BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOPENIA; LIVER GRAFT; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 78649665030     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00226.x     Document Type: Article

References (23)

1. Pescovitz MD,. (2006) Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 82 (Suppl 2): 4-8.
2. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG,. (1997) Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 126: 275-279.
3. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. (2006) Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81: 1645-1652.
4. Lautenschlager I,. (2009) CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl Int 22: 1031-1040.
5. Razonable RR,. (2008) Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 14: 4849-4860.
6. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG,. (2008) A survey of CMV prevention strategies after liver transplantation. Am J Transplant 8: 158-161.
7. Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil R,. (1997) Longterm ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seropositive donors. Transplantation 64: 1614-1617.
8. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. (1997) Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 350: 1729-1733.
9. Winston DW, Busuttil RW,. (2004) Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for longterm prophylaxis of cytomegalovirus diseases in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 77: 305-308.
10. Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA,. (2009) Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 15: 963-967.
11. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, et al. (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44: 2811-2815.
12. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. (2004) Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4: 611-620.
13. Roche Pharmaceuticals. 2009. Valcyte (valganciclovir hydrochloride tablets) package insert. [Accessed March 2010.
14. Greenberg RN,. (1984) Overview of patient compliance with medication dosing: a literature review. Clin Ther 6: 592-599.
15. Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, et al. (2005) Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 37: 3182-3186.
16. Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, et al. (2005) Valganciclovir Solid Organ Transplant Study Group. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 44: 495-507.
17. Arthurs SK, Eid AJ, Pederson RA, Dierkhising RA, Kremers WK, Patel R, et al. (2007) Delayed onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 13: 1703-1709.
18. Park JM, Lake KD, Arenas JD, Fontana RJ,. (2006) Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 12: 112-116.
19. Brady RL, Green K, Frei C, Maxwell P,. (2009) Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 11: 106-111.
20. Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, et al. (2008) Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 46: 20-27.
21. Razonable RR,. (2005) Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62 (Suppl 1): 7-13.
22. Singh N,. (2005) Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 40: 704-708.
23. Kijpittayarit S, Deziel P, Eid AJ, Razonable RR,. (2006) Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 81: 137-138.